AstraZeneca's shares surged after reporting strong Q1 financial results, with both top and bottom line exceeding expectations. CEO Pascal Soriot highlighted the company's remarkable growth in emerging markets, particularly outside of China. The positive earnings report led to a rally in Big Pharma and Managed Care stocks, including AstraZeneca, Merck, and Sanofi.
AstraZeneca’s earnings surprise investors as cancer drugs fuel growth https://t.co/6xdN2XqPQt @ByJonGardner $AZN + 6%
Big Pharma and Managed Care higher on a down day in the market. $SNY $AZN $MRK all rallying after earnings beat on the top and bottom line... https://t.co/oyunEA7luA
"We had a tremendous first quarter," AstraZeneca CEO Pascal Soriot says. "The most exciting part of it is every portfolio of products grew. ... The most remarkable was the growth in the emerging market outside of China, 40% growth." Full comments: https://t.co/35RKfgIGbN
$AZN (+5.3% pre) AstraZeneca leaps after smashing first-quarter forecasts https://t.co/XswqkD4SJv
AstraZeneca $AZN shares jump on much stronger Q1 top and bottom line https://t.co/tJuIvWX0Rb https://t.co/g3mxnTXNEx